Summary & Overview
CPT 81261: IGH Clonality Assay for Lymphoid Neoplasms
CPT code 81261 represents a molecular diagnostic laboratory test that detects clonal immunoglobulin heavy chain (IGH@) gene rearrangements associated with lymphoid neoplasms. This assay is clinically important for diagnosing and monitoring B‑cell malignancies and for distinguishing reactive from clonal lymphoid proliferations. Nationally, such molecular clonality testing underpins diagnostic pathways in hematopathology and informs downstream clinical management.
Key payers discussed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find a concise overview of the code’s clinical context, typical service setting, and the types of benchmarks and policy elements commonly reviewed for laboratory molecular codes: coverage considerations, coding and billing practice notes, utilization benchmarks, and common modifier usage. The report highlights where coding clarity matters for reimbursement and documentation and summarizes implications for laboratory service lines and hospital-based molecular diagnostics.
This summary is intended to orient clinical laboratory managers, coding professionals, and policy analysts to the purpose and scope of CPT code 81261, and to indicate the areas covered in the full publication: national payer coverage patterns, coding nuances, and clinical interpretation context. Data not available in the input is noted where applicable in the detailed sections.
Billing Code Overview
CPT code 81261 describes a laboratory test that detects clonal cell populations resulting from gene rearrangements in the Immunoglobulin heavy chain locus (IGH@). The procedure identifies clonal IGH rearrangements that are indicative of lymphoid neoplasms, enabling detection and monitoring of B‑cell clonality.
-
Service type: Molecular diagnostic assay / laboratory genetic test
-
Typical site of service: Clinical molecular laboratory or hospital-based laboratory performing specialized molecular diagnostics
This code covers the technical laboratory component of the assay performed by the lab analyst to detect presence of specific cell populations from IGH@ gene rearrangements.
Clinical & Coding Specifications
Clinical Context
A 62-year-old patient presents to a hematology/oncology clinic with progressive lymphadenopathy, unexplained cytopenias, and constitutional symptoms. The treating hematologist orders lymphoid clonality testing to evaluate for a suspected B-cell lymphoproliferative disorder. A tissue specimen (excisional lymph node) or peripheral blood sample is collected and sent to a reference molecular pathology laboratory. The laboratory technologist performs DNA extraction and a PCR-based or next-generation sequencing assay targeting the Immunoglobulin heavy chain locus (IGH@) to detect clonal IGH gene rearrangements. The lab analyst documents specimen receipt, runs the technical assay, interprets assay quality metrics, and reports the presence or absence of a dominant clonal IGH rearrangement that supports a diagnosis of a lymphoid neoplasm. Typical sites of service include hospital outpatient laboratories, independent reference laboratories, and hospital-based molecular pathology labs. The service type is a molecular diagnostic laboratory test (technical component) performed as part of the diagnostic workup for suspected B-cell lymphomas, chronic lymphocytic leukemia, or minimal residual disease monitoring in treated lymphoid malignancies.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
26 | Professional component | When reporting only the professional interpretation component if applicable and separable from the lab technical work. |